

PRESS RELEASE

CATTOLICA ASSICURAZIONI AND ROCHE ITALIA FOR PRECISION MEDICINE

*The agreement ensures access to the latest genomic profiling solutions using the services of **FOUNDATION MEDICINE** (part of the Roche Group) for in-depth diagnosis that allows for a personalised approach to cancer*

Verona, 29 June 2021. Cattolica Assicurazioni and Roche Italia have signed a collaboration agreement that enables rapid access to the precision diagnostic services of Foundation Medicine (part of the Roche Group) in the area of oncology for Active Benessere policyholders.

Cattolica policyholders with advanced or metastatic cancer will be able to access Foundation Medicine's innovative diagnostic services and take a specific genomic profiling test that, by applying innovative NGS (Next Generation Sequencing) technologies, can identify any DNA mutations responsible for tumour development. On the basis of the genomic profile identified, clinically relevant information can be obtained that will allow for the treatment pathway to be individualised, supporting clinicians in their choice of therapeutic treatment.

"The agreement with Roche Italia is an opportunity to provide Cattolica customers with access to state-of-the-art diagnostic services, identifying new parameters to gain a broad overview of the therapeutic opportunities available," explains **Carlalberto Crippa, Business Development & Marketing Director of the Cattolica Group**. - *In constructing our Health offer we decided to support prevention and protection by leveraging a partnership ecosystem that focuses on the health of the individual and that, on a large scale, helps to generate well-being for the community. Roche and Foundation Medicine are major players in this ecosystem, because they allow us to enrich our offering with concrete solutions in oncology, a priority medical field."*

"The agreement with Cattolica Assicurazioni, one of the first of its kind in Italy and Europe, is an excellent example of how the insurance and pharmaceutical industry can collaborate effectively," says **Marco Zanotti, New Business and Partnership Lead at Roche Italia**. *"We are opening new avenues in order to contribute to a more sustainable health system which will benefit patients as well as the scientific community and institutions. This*

combination of forces and mutual expertise is designed to achieve the ambitious goal of jointly creating new ways to give access to diagnostic and therapeutic innovation to as many patients as possible, reducing time and costs for the community."

Cattolica Assicurazioni is one of the main players on the Italian insurance market and has been listed on the Milan Stock Exchange since November 2000. With around 3.5 million customers who rely on the insurance solutions and products it distributes, the Group generates total premium income of €5.7 billion (2020). At the Group level, Cattolica has 1,360 agencies throughout Italy, covering both large cities and smaller towns, and a network of 1,851 agents. For further information: <https://www.cattolica.it/en/profile>

Roche Italia

For 125 years, Roche has been seeking ways to diagnose and treat highly complex diseases such as cancer, haemophilia, Alzheimer's, SMA and multiple sclerosis, creating value for society. The Group has three divisions in Italy: Roche S.p.A., Roche Diagnostics S.p.A. and Roche Diabetes Care S.p.A., a unique mixture of expertise in this market. In 2020, it invested €45 million in clinical research, with 210 research centres involved in more than 238 clinical trials and more than 17,850 patients receiving cutting-edge care at no cost to families or the national health service.

Foundation Medicine is a company specialising in molecular profiling that aims to transform the treatment of cancer, based on a deep understanding of the genomic mechanisms that are responsible for each individual patient's cancer, which is unique. The company offers innovative wide-ranging genomic profiling services to identify molecular alterations in cancer and combine them with targeted therapies, immunotherapies and active trials. The Foundation Medicine molecular information platform aims to improve day-to-day patient care by meeting the needs of physicians, researchers, and drug developers to help advance the science of molecular medicine in the field of oncology.

CATTOLICA ASSICURAZIONI CONTACT INFORMATION

Media Relations Manager

Erminia Frigerio (mob. 337/1165255)
erminia.frigerio@cattolicaassicurazioni.it

Local Media Manager

Angelo Cipriani (mob. 347/5074052)
angelo.cipriani@cattolicaassicurazioni.it

Comin & Partners

Lelio Alfonso (mob. 334/6054090 - 02/87042400)
lelio.alfonso@cominandpartners.com

Comin & Partners

Giuseppe Stamegna (mob. 392/0240063 - 06/9025523)
giuseppe.stamegna@cominandpartners.com

ROCHE CONTACT INFORMATION

Oncology Communications Manager

Sara Bernabovi
sara.bernabovi@roche.com
+39 342 7579993